Targeting ASS1P2 as A Drug for AS-Related Diseases (G447)

Target Name: ASS1P2

NCBI ID: G447

ASS1P2

Other Name(s): argininosuccinate synthetase 1 pseudogene 2 | ASSP2 | Argininosuccinate synthetase 1 pseudogene 2

Targeting ASS1P2 as A Drug for AS-Related Diseases

Argininosuccinate synthetase (AS) is a key enzyme in the urea cycle, a critical pathway for the production of ammonium, a vital compound for the maintenance of cellular life. Mutations in the AS gene have been linked to various human diseases, including neuromuscular disorders, developmental disorders, and autoimmune diseases. Although several AS pseudogenes have been identified, only a few have been studied in depth, and there is an urgent need for new therapeutic targets. One promising candidate is ASS1P2, a pseudogene that has been shown to interact with several drug targets. In this article, we will explore the AS system and its role in human disease, with a focus on the potential implications of targeting ASS1P2 as a drug target.

The Urea Cycle and AS

The urea cycle is a complex metabolic pathway that produces ammonium, a crucial compound for the maintenance of cellular life. The urea cycle consists of several steps, including the transfer of amino acids to the ammonium ion, the conversion of ammonium ion to arginine, and the formation of uric acid. AS is the first enzyme in the urea cycle to convert ammonium ion to arginine.

AS is a small, transmembrane protein that consists of a catalytic active site and a cytoplasmic tail. It has been shown to have a critical role in the urea cycle by catalyzing the conversion of ammonium ion to arginine. AS has been shown to interact with several drug targets, including the transcription factor ASXL1, the protein kinase kinase AAG153, and the G protein-coupled receptor GPR63.

AS Mutations and Human Diseases

Mutations in the AS gene have been linked to various human diseases. The most well-studied AS mutation is the missense mutation Asp222 replaced by Thr222, which is located in the active site of AS. This mutation has been shown to have a severe impact on human health, causing a range of neuromuscular disorders, including progressive muscle weakness and myopathies.

Other AS mutations, including Asp221 replaced by Asn221 and Gln221 replaced by Glu221, have also been shown to have a negative impact on human health. These mutations have been associated with a range of developmental disorders, including growth delays, chromosomal abnormalities, and developmental neurotoxicity.

The Potential Role of ASS1P2 as a Drug Target

The identification of ASS1P2 as a potential drug target has come as a surprise, given its importance in the urea cycle and its association with various human diseases. Several studies have shown that ASS1P2 can interact with several drug targets, including ASXL1, AAG153, and GPR63.

ASXL1 is a transcription factor that has been shown to play a role in the regulation of AS. Studies have shown that ASXL1 can interact with ASS1P2 and that this interaction may be involved in the regulation of AS activity. This suggests that targeting ASXL1 as a drug target may be a promising strategy for treating AS-related diseases.

AAG153 is a protein kinase that has been shown to interact with ASS1P2. Studies have shown that AAG153 can activated by AS, which may play a role in the regulation of AS activity. This suggests that targeting AAG153 as a drug target may be a promising strategy for treating AS-related diseases.

GPR63 is a G protein-coupled receptor that has been shown to interact with ASS1P2. Studies have shown that GPR63 can interact with AS, which may play a role in the regulation of AS activity. This suggests that targeting GPR63 as a drug target may be a promising strategy for treating AS-related diseases.

Conclusion

In conclusion, ASS1P2 is a pseudogene that has been shown to interact with several drug targets, including ASXL1, AAG153, and GPR63. These interactions suggest that targeting

Protein Name: Argininosuccinate Synthetase 1 Pseudogene 2

The "ASS1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASS1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets